Atossa Therapeutics Appoints CORE IR for Investor Relations, Shareholder Communications and Public Relations Services
Atossa Therapeutics (NASDAQ:ATOS), a clinical-stage biopharmaceutical company focused on breast cancer treatment and prevention, has appointed CORE IR as its strategic investor relations and communications partner. The collaboration aims to enhance investor awareness and strengthen shareholder engagement through comprehensive IR services.
Under the agreement, CORE IR will provide strategic messaging, non-deal roadshow support, investor targeting and outreach, and communication program support. The partnership reflects Atossa's commitment to improving market visibility and communicating its progress to both institutional and retail investors.
Atossa Therapeutics (NASDAQ:ATOS), una società biofarmaceutica in fase clinica focalizzata sul trattamento e sulla prevenzione del cancro al seno, ha nominato CORE IR come partner strategico di relazioni con gli investitori e comunicazioni. La collaborazione mira ad aumentare la consapevolezza degli investitori e a rafforzare l'engagement degli azionisti tramite servizi IR completi.
Secondo l'accordo, CORE IR offrirà messaggi strategici, supporto a roadshow non legati a operazioni, targeting e outreach agli investitori, e supporto al programma di comunicazione. La partnership riflette l'impegno di Atossa a migliorare la visibilità sul mercato e a comunicare i propri progressi sia agli investitori istituzionali che a quelli al dettaglio.
Atossa Therapeutics (NASDAQ:ATOS), una empresa biofarmacéutica en etapas clínicas enfocada en el tratamiento y la prevención del cáncer de mama, ha designado a CORE IR como su socio estratégico de relaciones con inversores y comunicaciones. La colaboración busca aumentar la visibilidad ante los inversores y fortalecer el compromiso de los accionistas mediante servicios integrales de IR.
Según el acuerdo, CORE IR proporcionará mensajes estratégicos, apoyo a roadshows sin operaciones, segmentación y alcance a inversores, y apoyo al programa de comunicaciones. La alianza refleja el compromiso de Atossa de mejorar la visibilidad en el mercado y comunicar sus avances tanto a inversores institucionales como minoristas.
Atossa Therapeutics(NASDQ:ATOS)는 임상단계의 바이오제약 기업으로 유방암 치료 및 예방에 집중하고 있으며, CORE IR를 전략적 투자자 관계 및 커뮤니케이션 파트너로 임명했습니다. 이번 협업은 포괄적인 IR 서비스를 통해 투자자 인식을 높이고 주주 참여를 강화하는 것을 목표로 합니다.
계약에 따라 CORE IR은 전략적 메시지 구성, 비거래 로드쇼 지원, 투자자 타깃팅 및 아웃리치, 커뮤니케이션 프로그램 지원을 제공합니다. 이 파트너십은 기관 및 소매 투자자 모두에게 시장 가시성을 개선하고 진행 상황을 전달하려는 Atossa의 약속을 반영합니다.
Atossa Therapeutics (NASDAQ:ATOS), une société biopharmaceutique en phase clinique axée sur le traitement et la prévention du cancer du sein, a nommé CORE IR comme partenaire stratégique en relations investisseurs et communications. Cette collaboration vise à accroître la notoriété auprès des investisseurs et à renforcer l’engagement des actionnaires grâce à des services IR complets.
Selon l’accord, CORE IR fournira des messages stratégiques, un soutien aux roadshows non liés à des transactions, le ciblage et la prise de contact des investisseurs, ainsi que le soutien au programme de communication. Le partenariat reflète l’engagement d’Atossa à améliorer la visibilité sur le marché et à communiquer ses progrès aussi bien aux investisseurs institutionnels qu’aux investisseurs de détail.
Atossa Therapeutics (NASDAQ:ATOS), ein klinisch beforschendes Biopharmaunternehmen mit Schwerpunkt auf Brustkrebsbehandlung und -prävention, hat CORE IR als strategischen Investor-Relations- und Kommunikationspartner ernannt. Die Zusammenarbeit soll das Anlegerbewusstsein erhöhen und das Engagement der Aktionäre durch umfassende IR-Dienstleistungen stärken.
Gemäß der Vereinbarung wird CORE IR strategische Botschaften, Unterstützung bei non-deal roadshows, Investoren-Targeting und Outreach sowie Unterstützung des Kommunikationsprogramms bieten. Die Partnerschaft spiegelt Atossas Engagement wider, die Markttransparenz zu verbessern und seine Fortschritte sowohl institutionellen als auch privaten Investoren zu vermitteln.
Atossa Therapeutics (NASDAQ:ATOS)، شركة أدوية حيويّة في مرحلة سريرية تركز على علاج ووقاية سرطان الثدي، عينت CORE IR كشريك استراتيجي للعلاقات مع المستثمرين والاتصالات. تهدف الشراكة إلى زيادة الوعي بين المستثمرين وتعزيز تفاعل المساهمين من خلال خدمات IR شاملة.
بموجب الاتفاق، ستقدّم CORE IR رسائل استراتيجية، ودعمًا لجولات الطريق غير المتعلقة بصفقات، وتوجيهًا وتواصلًا مع المستثمرين، ودعمًا لبرنامج الاتصالات. تعكس الشراكة التزام Atossa بتحسين وضوح السوق ونقل تقدمها إلى كل من المستثمرين المؤسسيين والتجزئة.
Atossa Therapeutics（NASDAQ:ATOS），一家处于临床阶段的生物制药公司，专注于乳腺癌治疗与预防，已任命CORE IR为其战略投资者关系与公关合作伙伴。此次合作旨在通过全面的IR服务提高投资者知名度并加强股东参与。
根据协议，CORE IR 将提供战略性信息传递、非交易路演支持、投资者定位与外联，以及公关计划支持。该伙伴关系体现了Atossa提升市场知名度、向机构与散户投资者传达公司进展的承诺。
- None.
- None.
Engagement to enhance investor awareness, strengthen shareholder engagement, and broaden reach to target institutional and retail audiences
SEATTLE, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS; “Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing new approaches in breast cancer treatment and prevention, today announces it has appointed CORE IR, a strategic investor relations, public relations, and corporate advisory firm, to support the Company’s ongoing investor relations and communications initiatives. CORE IR specializes in emerging and established growth company strategies that enhance investor awareness, strengthen shareholder engagement, and broaden reach to target institutional and retail audiences.
Dr. Steven Quay, Chairman and CEO of Atossa, commented, “Our collaboration with CORE IR represents our continued commitment to drive value for our stakeholders and with the investment community. We are executing to plan and excited to communicate our progress with increasing market visibility. We believe CORE IR’s stewardship will help us better articulate our value proposition to existing and prospective shareholders.”
Under the terms of the engagement, CORE IR will provide a comprehensive suite of investor relations services including strategic messaging, non-deal roadshow support, investor targeting and outreach, and support for Atossa’s communication programs.
“We are gratified to partner with Atossa on their important journey,” said Scott Gordon, Co-Founder and President of CORE IR. “The Company is focused on advancing breast cancer prevention and treatment by pioneering new therapies with innovative science. We look forward to helping the company increase its engagement with the broader investment community.”
About Atossa Therapeutics
Atossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company dedicated to transforming breast cancer treatment through innovative science and patient-focused solutions. The Company's lead product candidate, (Z)-endoxifen, is a highly potent SERM/D designed for use across the breast cancer spectrum, including risk-reduction, and treatment in the neoadjuvant, adjuvant, and metastatic settings. Atossa is committed to advancing its robust clinical research programs to improve patient outcomes while creating sustainable value for shareholders. For more information, visit atossatherapeutics.com.
Contacts:
Investors
CORE IR
ir@atossatherapeutics.com
(212) 655-0924
Media
Jules Abraham
CORE IR
pr@atossatherapeutics.com
(212) 655-0924
FAQ
What services will CORE IR provide to Atossa Therapeutics (NASDAQ:ATOS)?
Why did Atossa Therapeutics (NASDAQ:ATOS) appoint CORE IR?
What is Atossa Therapeutics' (NASDAQ:ATOS) main business focus?
Who announced the partnership between Atossa and CORE IR?
